drugset / Trial / NCT05690581
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
Timeline
- Start
- 2023-02-23
- Primary completion
- 2025-10-30
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM369 | Unknown | — | — |
Indications
No indication recorded.